Merck & Co., Inc. News
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
see moreMerck & Co., Inc. Market News
6d
Merck's FDA Approval of Lipfendra and Strategic Moves Propel Stock to New Heights
- Merck's Lipfendra approval and strategic acquisitions boost stock performance.
13d
Merck's Recent Developments and Their Impact on Stock Performance
Analyzing Merck's strategic moves and stock fluctuations in the pharmaceutical and animal health sectors.
19d
Merck's Strategic Moves Amidst Market Challenges: A Comprehensive Overview
Merck's recent strategic initiatives and market challenges analyzed.
18 Mar at 07:24
Merck: Keytruda Cliff, Split Plan, Exzolt Upside
Merck is navigating a near-term pharmaceutical revenue hit from looming Keytruda patent expirations and generics while its animal health unit gains momentum after FDA conditional approval of Exzolt Cattle-CA1. A proposed oncology split aims to isolate value, leaving investors to weigh short-term earnings risk against diversified growth drivers.
11 Mar at 07:25
Merck: NUMELVI FDA OK, Insider Sale Raises Flags!
Merck's animal-health win (NUMELVI FDA approval) and strong Q4 results bolster revenue diversification, while a large insider sale and offsetting vaccine softness temper near-term sentiment. Institutional buying adds weight to investor confidence.
04 Mar at 07:24
Merck Surges on Keytruda Ovarian Data, Numelvi Win
Merck (MRK) climbed after late‑February clinical data showed Keytruda improved overall survival in ovarian cancer and the company secured an FDA approval in veterinary dermatology (Numelvi). Institutional buying and positive HIV Phase 3 readouts further supported investor confidence, prompting analyst price‑target upgrades and a notable uptick in MRK shares.
